Compare Merck & Co., Inc. (MRK) vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) (RELX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) — how do they compare? Merck & Co., Inc. trades at $149.8 (market cap $363.59B), while RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) trades at $38.04 (market cap $63.89B). The key difference: Merck & Co., Inc. is far larger — about 5.7× RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)'s market cap, and RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share) pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| MRK | RELX | |
|---|---|---|
Market Cap | $363.59B | $63.89B |
Volume | 8,036,558 | 2,760,502 |
Sector | Health | Industrials |
52-Week High | $156.43 | $46.80 |
52-Week Low | $82.49 | $27.73 |
Typical Hold Time | 98 Days | — |
Enterprise Value | $410.35B | $75.40B |
Dividend Yield | 2.31% | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $141.98, down 2.39% on the day, with a bullish technical signal from moving averages and a neutral RSI. Revenue grew to $65.01B in 2025, with net income of $18.25B and a profit margin of 28.07%. Recent news highlights the acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors increased holdings. The stock shows strong earnings beats in recent quarters, with Q3 2026 results pending.
The outlook remains positive with a consensus price target of $158.50, implying 11.6% upside, supported by 68% analyst buy ratings. Risks include high P/E of 113.58, debt-to-asset ratio rising to 36.06% in 2025, and competitive pressures in pharmaceuticals. The acquisition strategy may drive growth but carries integration risks.
RELX trades at $36.70, up 0.44% with neutral technical signals. The company demonstrates strong profitability with 23.27% net margins and 132.36% ROE, though valuation metrics appear elevated with P/E of 22.21 and P/B of 38.89. Recent earnings show mixed results with Q2 2026 beating expectations while Q4 2025 missed. Analyst sentiment remains positive with 71% buy ratings and consensus price target of $26.00.
The investment case balances strong fundamentals against premium valuation. Growth catalysts include AI-driven product adoption and margin expansion, while risks involve competitive pressures and valuation concerns. With solid cash flow generation and institutional support, RELX offers quality exposure but requires monitoring of valuation multiples and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About RELX PLC PLC American Depositary Shares (Each representing One Ordinary Share)
RELX PLC is a UK-based information and analytics company operating across four segments: Risk (fraud prevention and compliance analytics via LexisNexis Risk Solutions), Scientific, Technical & Medical (Elsevier's research and clinical content), Legal (LexisNexis Legal & Professional's research tools), and Exhibitions (RX's trade events). It serves professional, business, and government customers worldwide.
Read more on RELX →
